RFA-DE-23-008: Data-Driven Tools to Accelerate the Clinical Translation of Novel Dental, Oral, and Craniofacial Biomaterials (Fast-Track - R44 - Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $750,000 to small businesses. Applications closed on November 9, 2022.
From the official notice on Grants.gov, last changed August 2, 2022. Checked November 7, 2026.
- Award ceiling$750,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR44
- Clinical trialsNot allowed
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DE-23-008 in the NIH Guide.
Key dates
| Posted | August 2, 2022 |
|---|---|
| Deadline | November 9, 2022 |
| Archived by Grants.gov | December 15, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full announcement for additional details on eligibility.
Is this a realistic fit?
- Past Oral Diseases and Disorders Research awards averaged $818,037; this notice allows up to $750,000 per award.
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Who has won Oral Diseases and Disorders Research grants before
From fiscal 2021 to 2025, Oral Diseases and Disorders Research (93.121) awarded $1.9 billion across 2,263 grant awards, an average of $818,037 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 76 | $89.2 million |
| The Regents of the University of California, San Francisco | California | 84 | $80.5 million |
| University of Southern California | California | 41 | $78.6 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 58 | $55.9 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 66 | $51.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DE-23-008 still open?
No. It closed on November 9, 2022.
Who can apply for Data-Driven Tools to Accelerate the Clinical Translation of Novel Dental, Oral, and Craniofacial Biomaterials (Fast-Track - R44 - Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Data-Driven Tools to Accelerate the Clinical Translation of Novel Dental, Oral, and Craniofacial Biomaterials (Fast-Track - R44 - Clinical Trial Not Allowed)?
Closed November 9, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)